BNTX · Healthcare
Biontech Se
26/100
Smart-money confidence1 of 3 sources positive
Weak — few signals
No standout activity across the feeds we track.
Hedge funds
34
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$23.4B
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqGS
About BIONTECH SE
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human…
Who's behind the signal
Every informed buyer we can see on BNTX, across all three feeds.
Hedge funds · 6
ARK Invest (Cathie Wood)
New position
Citadel Advisors
Increased +40%
Tudor Investment (Paul Tudor Jones)
Increased +162%
Baillie Gifford & Co
Decreased −29%
D.E. Shaw & Co
Decreased −59%
Millennium Management (Englander)
Decreased −87%
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar.
BIONTECH SE isn't in the top-10 model right now, but 6 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
6
Investors
1
New positions
2
Increasing
3
Decreasing
0
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.3×
% of portfolio
0.1%
Position change
NEW
0.1% of ARK Invest's portfolio
Trust weight: 1.0×
% of portfolio
0.1%
Position change
+40%
0.1% of Citadel Advisors's portfolio
Trust weight: 1.2×
% of portfolio
0.0%
Position change
+162%
0.0% of Tudor Investment's portfolio
Trust weight: 1.4×
% of portfolio
0.1%
Position change
−29%
0.1% of Baillie Gifford & Co's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−59%
0.0% of D.E. Shaw & Co's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−87%
0.0% of Millennium Management's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to BIONTECH SE
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell BIONTECH SE or any security.
订阅每周更新
我们每周会把巴菲特、达利欧、阿克曼以及另外 47 位传奇投资人正在买入的股票发送给你 — 免费，直接来自他们的 SEC 申报文件。
永久免费 · 无垃圾邮件 · 随时退订